Frank Diamond
Managing Editor
MANAGED CARE August 2011. ©MediMedia USA

The resulting company could control 40 percent of the PBM market, but would any savings be passed on to insurers?

Managing Editor

If Express Scripts and Medco Health Solutions ever actually consummate their planned $29 billion merger, what will that mean for health plans and other payers?

There are some real concerns about the merger, after all. “My first reaction was like everybody else’s,” says Sadhna Paralkar, MD, a health management consultant at Segal. “That this will reduce competition and will ultimately raise health care costs for the clients, because that’s what usually happens when the competition goes down.”

Expect the two pharmacy benefit managers to testify to the Federal Trade Commission (which has to rule on the match, considering antitrust concerns) that because the resulting company would have more bargaining power with drug companies, it could force lower prices.

But as Paralkar’s colleague, Edward A. Kaplan (a Segal Co. benefit consultant) tells the New York Times, “The question is, Will they pass it on to the buyer or will they keep it for earnings?”

Paralkar says that the more she thought about it, the more she felt that such a merger might “give some other smaller and not-so-well-known PBM carriers some much needed momentum. Something like UnitedHealth’s PBM, which is Optum RX, could become a commercializable entity where it could serve other customers.”

Expect the approval process to be grueling, she says. “The bigger the carrier gets or the vendor gets, the less people tend to trust it because of its power, and they are suspicious of its willingness to work on your behalf as a client,” says Paralkar.

In a discussion with Wall Street analysts on July 27, Aetna CEO Mark Bertolini was asked about the Express Scripts-Medco merger, and he indicated that he did not view it as a threat. He alluded to the deal struck last year between Aetna and CVS Caremark in which the PBM will oversee the insurer’s prescription drug program for 12 years.

“We believe that the deal we did with CVS … gives us as good a position as any other deal in the marketplace and any independent PBM in the marketplace.... We believe the Express Scripts-Medco merger presents a potential for some opportunities should there be fallout as part of the integration.”

Still, as the Times reports, “Consumer groups have already raised concerns with the commission over whether CVS Caremark, the result of a merger between a large drugstore chain and a pharmacy benefit manager, is hurting competition, and regulators are likely to want to prevent the [Express Scripts-Medco] merger if they have similar worries that it will stifle competition.”

If the merger is approved, the new company could corner about 40 percent of the market, Adam J. Fein, an industry consultant, tells the newspaper. CVS Caremark controls about 16 percent of the market, he says.

Different strengths

The Times notes that in some ways the benefits of the merger are obvious to the companies involved. “Express Scripts has specialized in understanding patients’ behavior and why they may not take their medicines, while Medco has emphasized clinical expertise to determine which medicines work best.”

Analysts told the newspaper that the deal “could fundamentally change the dynamics of the market for overseeing prescription drug use for health plans and employers...”

“I have a feeling that it is not going to be as bad as people anticipate,” says Sadhna Paralkar, MD, a Segal consultant.

Managed Care’s Top Ten Articles of 2016

There’s a lot more going on in health care than mergers (Aetna-Humana, Anthem-Cigna) creating huge players. Hundreds of insurers operate in 50 different states. Self-insured employers, ACA public exchanges, Medicare Advantage, and Medicaid managed care plans crowd an increasingly complex market.

Major health care players are determined to make health information exchanges (HIEs) work. The push toward value-based payment alone almost guarantees that HIEs will be tweaked, poked, prodded, and overhauled until they deliver on their promise. The goal: straight talk from and among tech systems.

They bring a different mindset. They’re willing to work in teams and focus on the sort of evidence-based medicine that can guide health care’s transformation into a system based on value. One question: How well will this new generation of data-driven MDs deal with patients?

The surge of new MS treatments have been for the relapsing-remitting form of the disease. There’s hope for sufferers of a different form of MS. By homing in on CD20-positive B cells, ocrelizumab is able to knock them out and other aberrant B cells circulating in the bloodstream.

A flood of tests have insurers ramping up prior authorization and utilization review. Information overload is a problem. As doctors struggle to keep up, health plans need to get ahead of the development of the technology in order to successfully manage genetic testing appropriately.

Having the data is one thing. Knowing how to use it is another. Applying its computational power to the data, a company called RowdMap puts providers into high-, medium-, and low-value buckets compared with peers in their markets, using specific benchmarks to show why outliers differ from the norm.
Competition among manufacturers, industry consolidation, and capitalization on me-too drugs are cranking up generic and branded drug prices. This increase has compelled PBMs, health plan sponsors, and retail pharmacies to find novel ways to turn a profit, often at the expense of the consumer.
The development of recombinant DNA and other technologies has added a new dimension to care. These medications have revolutionized the treatment of rheumatoid arthritis and many of the other 80 or so autoimmune diseases. But they can be budget busters and have a tricky side effect profile.

Shelley Slade
Vogel, Slade & Goldstein

Hub programs have emerged as a profitable new line of business in the sales and distribution side of the pharmaceutical industry that has got more than its fair share of wheeling and dealing. But they spell trouble if they spark collusion, threaten patients, or waste federal dollars.

More companies are self-insuring—and it’s not just large employers that are striking out on their own. The percentage of employers who fully self-insure increased by 44% in 1999 to 63% in 2015. Self-insurance may give employers more control over benefit packages, and stop-loss protects them against uncapped liability.